Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1384012Generated: October 31, 2026

4-(Prop-2-enyl)-2-[(4-chlorophenoxy)methyl]-1-[3-[1-(t-butoxycarbonyl)piperidin-4-yl]propyl]benzimidazole → 4-(Propyl)-2-[(4-chlorophenoxy)methyl]-1-[3-[1-(t-butoxycarbonyl)piperidin-4-yl]propyl]benzimidazole

https://huagongshe.com/reaction/1384012

Reaction equation

Participants

RoleNameHCIDCharge
Reactant4-(Prop-2-enyl)-2-[(4-chlorophenoxy)methyl]-1-[3-[1-(t-butoxycarbonyl)piperidin-4-yl]propyl]benzimidazoleHCID 21188821—
ReactantHCID 178418361HCID 178418361—
CatalystPalladiumHCID 23938—
SolventEthyl AcetateHCID 8857—
Product4-(Propyl)-2-[(4-chlorophenoxy)methyl]-1-[3-[1-(t-butoxycarbonyl)piperidin-4-yl]propyl]benzimidazoleHCID 21188572—

Reaction Steps

In a 50 ml sinfle neck round bottom flask, under a nitrogen atmosphere, 4-(prop-2-enyl)-2-[(4-chlorophenoxy)methyl]-1-[3-[1-(t-butoxycarbonyl)piperidin-4-yl]propyl]benzimidazole (100 mg, 0.19 mmol) was added to ethyl acetate (4 ml). To this solution was added 10% palladium on activated carbon (100 mg), followed by the addition of a hydrogen balloon. The reaction mixture was stirred for three hours at room temperature, then filtered through a bed of CELITE™. The desired title product was further purified by radial chromatography.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS06255494B1
Source datasetuspto-grants-2001_07
ORD IDord-1b1a4f76263e4e018402dc711b28c71b
Source noteuspto-grants-2001_07